| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2014-09-04 | Picato® (ingenol mebutate) | actinic keratosis |
Leo Pharma (Denmark) | Dermatological diseases | |
| 2014-09-04 | odilorhabdins (NOSO-95) | preclinical | Nosopharm (France) | Infectious diseases | |
| 2014-09-04 | 12G4 monoclonal antibody | ovarian cancer |
preclinical | GamaMabs Pharma (France) | Cancer - Oncology |
| 2014-09-04 | ThermoDox® (encapsulated doxorubicin) | recurrent chest wall breast cancer |
1 | Celsion (USA - NJ) | Cancer - Oncology |
| 2014-09-03 | myRisk™ Hereditary Cancer test | breast cancer |
Myriad Genetics (USA - UT) | Cancer - Oncology | |
| 2014-09-02 | Xarelto® (rivaroxaban) | patients with non-valvular atrial fibrillation undergoing cardioversion |
3b | Bayer Healthcare (Germany) | Cardiovascular diseases |
| 2014-09-02 | F901318 (2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]- phenyl}-2-oxo-acetamide) | invasive aspergillosis and other life-threatening fungal infections | 1 | F2G (UK) | Infectious diseases |
| 2014-09-02 | SAGE-217 | seizure conditions, including orphan genetic epilepsy disorders, such as Rett syndrome and Dravet syndrome | preclinical | Sage Therapeutics (USA - MA) | CNS diseases - Genetic diseases - Neurological diseases - Rare diseases |
| 2014-09-02 | aramchol | NASH (non-alcoholic steatohepatitis) |
preclinical | Galmed Pharmaceuticals (Israel) | Hepatic diseases - Liver diseases |
| 2014-09-02 | ThermoDox® (encapsulated doxorubicin) in combination with optimized radiofrequency ablation | hepatocellular carcinoma |
3 | Celsion (USA - NJ) | Cancer - Oncology |
| 2014-09-02 | CPP-115 | 1b | Catalyst Pharmaceutical Partners (USA - FL) | Rare diseases | |
| 2014-09-01 | XEN-D0103 | atrial fibrillation |
2 | Servier (France) Xention (UK) | Cardiovascular diseases |
| 2014-09-01 | Brilinta®/Brilique™ (ticagrelor) | reduction of heart attacks and cardiovascular death in patients with acute coronary syndrome |
4 | AstraZeneca (UK) | Cardiovascular diseases |
| 2014-08-30 | Eliquis® (apixaban) | prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) |
3 | BMS (USA - NY) Pfizer (USA - NY) | Cardiovascular diseases |
| 2014-08-29 | Xarelto® (rivaroxaban) | acute coronary syndrome (ACS, stroke of undetermined source (ESUS) - peripheral artery disease (PAD) | 2-3 | Janssen Research & Development, a J&J company (USA - NJ) - Bayer Healthcare (Germany) | Cardiovascular diseases |
| 2014-08-26 | Sivextro™ (tedizolid phosphate) | acute bacterial skin and skin structure infections (ABSSSI) |
Cubist Pharmaceuticals (USA - MA) | Infectious diseases | |
| 2014-08-26 | ceftolozane/tazobactam | Cubist Pharmaceuticals (USA - MA) | Infectious diseases | ||
| 2014-08-26 | combination of XALKORI® (crizotinib) and pembrolizumab | ALK-positive advanced or metastatic non-small cell lung cancer (NSCLC) |
1b | Merck&Co (USA - NJ) Pfizer (USA - NY) | Cancer - Oncology |
| 2014-08-26 | biomarkers for Parkinson\'s disease ( quantitative pilomotor axon-reflex test (QPART) technique) | Parkinson\'s disease |
Prothena (Ireland) | Neurodegenerative diseases | |
| 2014-08-25 | HPV diagnostic test using the DNA molecular combing process | human papillomavirus (HPV) infection |
Genomic Vision (France) | Infectious diseases |
